Table of Contents
If you run a telehealth company, choosing a compounding pharmacy is not just about finding someone who can fill a prescription.
It affects how you fulfill prescriptions, how much inventory flexibility you have, how your pharmacy relationships work, what kind of operational model you can build, and how much compliance responsibility sits inside your workflow.
And when GLP-1s are involved, the distinction becomes even more important.
You will hear the terms 503A pharmacy and 503B outsourcing facility constantly in conversations about compounded medications. They are both part of the federal compounding framework, but they are not interchangeable.
So what actually separates them?
503A vs. 503B: The Basic Difference
At a high level, Section 503A applies to traditional pharmacy compounding, while Section 503B creates a category of FDA-registered outsourcing facilities.
Under 503A, compounding is generally performed by a licensed pharmacist in a state-licensed pharmacy or by a licensed physician, and the drug is compounded for an individual patient based on a valid prescription. Under 503B, compounding takes place in an outsourcing facility that has registered with FDA and operates under a different set of requirements.
That sounds like a small distinction.
Operationally, it isn’t.
A telehealth company working with one or more pharmacies needs to understand what the pharmacy is actually set up to do before building its fulfillment workflow around it.
503A vs. 503B at a glance
| 503A Pharmacy | 503B Outsourcing Facility | |
| Primary model | Traditional pharmacy compounding | Outsourcing facility |
| FDA registration as outsourcing facility | No | Yes |
| Patient-specific prescription | Generally required | Not always required |
| Can compound for office stock | No under the 503A framework | Yes, subject to applicable requirements |
| CGMP requirements | 503A exemptions include CGMP requirements when all conditions are met | Must comply with CGMP requirements |
| FDA inspection | Primarily state oversight, with federal requirements also applying | FDA inspection on a risk-based schedule |
| Distribution model | Primarily tied to individual patients | Can compound for identified patients or in response to certain healthcare-provider orders |
| Best understood as | Patient-specific pharmacy compounding | Larger-scale outsourcing model |
FDA makes an important distinction here: a 503B facility is not simply a “bigger 503A pharmacy.” It is a different regulatory category with different requirements.
That distinction matters when a telehealth business starts scaling.
What Is a 503A Pharmacy?
A 503A pharmacy is generally focused on patient-specific compounding.
Think about the workflow this way:
A provider evaluates a patient → determines that a compounded medication is appropriate → sends a prescription → the pharmacy compounds the medication for that patient.
The patient-specific prescription is a core part of the 503A framework.
503A pharmacies can be a good fit when a telehealth business has a relatively straightforward patient-specific fulfillment model and needs the flexibility that traditional pharmacy compounding can provide.
But there is an important limitation for growing businesses.
You cannot simply treat a 503A pharmacy like a manufacturing facility and assume you can order large quantities of compounded medication ahead of patient demand.
The regulatory framework matters.
For example, FDA says 503A compounders generally cannot regularly or inordinate amounts compound drugs that are essentially copies of commercially available products, subject to the applicable statutory and regulatory conditions.
That is one reason telehealth companies need to look beyond the pharmacy’s ability to fill prescriptions today.
They need to understand whether the model will still work when prescription volume doubles.
What Is a 503B Outsourcing Facility?
A 503B outsourcing facility operates under a different framework.
These facilities register with FDA and must comply with current good manufacturing practice, or CGMP, requirements. FDA also inspects outsourcing facilities according to a risk-based schedule.
One major operational difference is that a 503B outsourcing facility may compound medications without first receiving a prescription for an identified individual patient. This can allow certain healthcare organizations to order compounded drugs as office stock, subject to the applicable requirements.
For a growing healthcare business, that distinction can be significant.
Instead of thinking only about individual prescription fulfillment, the conversation can move toward supply, production capacity, inventory planning, and broader fulfillment operations.
But there is a catch.
503B does not mean “FDA-approved pharmacy.”
It does not mean the compounded drug itself has gone through the FDA’s premarket approval process.
FDA specifically notes that drugs made by outsourcing facilities are not FDA-approved, and registration does not mean FDA has determined that a facility is compliant with CGMP requirements.
That is an important distinction for telehealth companies making claims on their websites and in marketing materials.
503A vs. 503B Compounding: Why Telehealth Companies Care
For a telehealth operator, the question isn’t simply:
“Which pharmacy is better?”
The better question is:
“Which pharmacy model fits the way our business actually operates?”
Consider a telehealth company with 200 prescriptions a month.
Its needs may be very different from a company processing 20,000 prescriptions across multiple states.
The pharmacy relationship has to keep up with the business.
A few questions worth asking:
- Are prescriptions always patient-specific?
- Does the pharmacy support the states where you operate?
- What happens when prescription volume spikes?
- How quickly can prescriptions be routed and acknowledged?
- How are refill requests handled?
- How are exceptions communicated?
- Can the pharmacy provide useful fulfillment status information?
- How are recalls or quality issues communicated?
- What documentation can the pharmacy provide?
- Is the pharmacy actually operating under the regulatory framework it claims to use?
These questions may sound operational.
They are also compliance questions.
A telehealth company can have a compliant clinical workflow and still create problems if the pharmacy relationship, prescription routing, fulfillment process, or marketing claims are poorly managed.
Can 503A and 503B Pharmacies Compound GLP-1 Medications?
This is where things get complicated.
The short answer is: potentially, but not simply because a pharmacy is 503A or 503B.
The regulatory pathway depends on the specific drug, active pharmaceutical ingredient, formulation, shortage status, applicable compounding requirements, and other federal and state requirements.
FDA’s April 2026 guidance reinforced that compounders must satisfy the applicable conditions under Sections 503A or 503B. For 503A, for example, the drug generally must be compounded for an individual patient pursuant to a prescription, and restrictions apply when the compounded product is essentially a copy of a commercially available drug.
For 503B facilities, bulk drug substances generally must meet specific statutory requirements, including appearing on the applicable 503B bulks list or being used to compound a drug that appears on FDA’s drug shortage list at the relevant time.
And this is particularly important with GLP-1s because the regulatory landscape has been changing.
FDA has also warned about quality and safety concerns involving compounded GLP-1 products and says compounded drugs should generally be used when a patient’s medical needs cannot be met by an FDA-approved drug.
So a telehealth company should never assume:
“It’s a 503A pharmacy, therefore it can compound this GLP-1.”
Or:
“It’s a 503B facility, therefore it can supply this medication at scale.”
The actual product and legal pathway still need to be evaluated.
The 503A vs. 503B Decision Is Really an Operations Decision
For telehealth companies, pharmacy selection often happens too late.
The business launches first.
Patient volume grows.
Then someone realizes that prescriptions are being routed manually, pharmacy responses are coming through different channels, refill requests are sitting in inboxes, and nobody has a reliable view of what happened to a prescription after it left the provider workflow.
That is when the pharmacy relationship becomes an operational problem.
The better approach is to think about pharmacy infrastructure before volume gets painful.
If you’re evaluating a 503A pharmacy
Look closely at:
Patient-specific fulfillment
Can the pharmacy reliably support the prescription volume and patient-specific workflow your model requires?
State coverage
Where is the pharmacy licensed, and where can it legally dispense?
Prescription routing
How will prescriptions get from your provider workflow to the pharmacy?
Refills
What happens when a patient needs a refill?
Communication
How are missing information, rejected prescriptions, or fulfillment issues communicated?
Capacity
What happens during a sudden increase in prescription volume?
If you’re evaluating a 503B outsourcing facility
Look at those same operational questions, but add:
Registration status
Verify that the specific facility is currently registered as a 503B outsourcing facility. FDA maintains a current list of registered outsourcing facilities, including registration and inspection information.
CGMP compliance
503B facilities are subject to CGMP requirements, so quality systems and inspection history deserve attention.
Product eligibility
Don’t assume every medication or bulk substance can be compounded simply because the facility is registered.
Supply capacity
Understand production capacity, lead times, inventory policies, and what happens when demand changes.
Product reporting
503B outsourcing facilities have product reporting obligations to FDA, including reporting compounded products during specified reporting periods.
Don’t Confuse “503B” With “Better”
This is probably the most important point for telehealth founders.
There is no universal rule that says:
503B = better
or
503A = safer
The two frameworks exist for different compounding models.
A 503B facility has additional federal requirements, including CGMP requirements and FDA registration and inspection. But that does not make every 503B facility automatically appropriate for every telehealth business.
Likewise, a 503A pharmacy isn’t automatically the wrong choice because it operates under a patient-specific model.
The right question is whether the pharmacy’s regulatory status, capabilities, geography, product portfolio, capacity, and workflow fit your business.
What Telehealth Brands Should Audit Before Choosing a Compounding Pharmacy
Before signing a pharmacy partnership, run through this checklist.
Pharmacy verification
☐ Confirm the pharmacy’s licensing and jurisdictions
☐ Confirm whether the facility operates under 503A or is registered under 503B
☐ For a 503B facility, verify its current FDA registration
☐ Review available inspection and enforcement information
☐ Understand who actually compounds the medication
Product verification
☐ Confirm which medications the pharmacy can legally compound
☐ Check applicable bulk substance requirements
☐ Review current FDA shortage and compounding policies where relevant
☐ Don’t assume GLP-1 eligibility based solely on the pharmacy’s 503A or 503B status
Operational verification
☐ Map the prescription-routing workflow
☐ Define how pharmacy acknowledgements are received
☐ Establish a process for rejected or delayed prescriptions
☐ Map refill workflows
☐ Define escalation procedures
☐ Establish how medication exceptions are communicated
☐ Know what fulfillment visibility your team will have
Marketing and compliance verification
☐ Review claims about compounded medications
☐ Don’t describe compounded drugs as FDA-approved
☐ Don’t describe a pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed”
☐ Make sure product descriptions accurately identify the compounder and medication
FDA has specifically taken action over misleading claims involving compounded semaglutide and tirzepatide, including claims suggesting that compounded products were FDA-approved and claims describing facilities as “FDA licensed.”
That is a good reminder that compliance isn’t confined to the pharmacy.
The telehealth company’s website, sales materials, patient communications, and operational workflows can all become part of the picture.
503A vs. 503B: The Question Telehealth Brands Should Really Ask
Choosing between a 503A pharmacy and a 503B outsourcing facility isn’t about picking a winner.
It’s about matching the pharmacy model to your clinical, regulatory, and operational requirements.
A smaller telehealth business with patient-specific prescriptions may have very different needs from a national platform managing thousands of prescriptions across multiple pharmacy relationships.
And once you start scaling, pharmacy infrastructure becomes harder to ignore.
Prescription routing, pharmacy coordination, refill management, fulfillment visibility, exception handling, and provider workflows all have to work together.
That’s where infrastructure matters.
RxAve helps telehealth companies connect prescription routing, pharmacy coordination, refill management, and fulfillment workflows through a connected infrastructure layer, giving teams better visibility into what happens after a prescription leaves the provider workflow.
The pharmacy is only one part of the system.
The real challenge is making the entire system work together.
FAQs
What is the difference between a 503A and 503B pharmacy?
The biggest difference is the regulatory framework and operating model. A 503A pharmacy generally compounds for individual patients based on prescriptions. A 503B outsourcing facility registers with FDA, is subject to CGMP requirements, and can compound for identified patients or, under applicable rules, in response to certain provider orders without a patient-specific prescription.
Which is better for telehealth companies, 503A or 503B?
Neither is automatically better. It depends on your prescription volume, patient-specific workflow, geographic footprint, product needs, fulfillment model, and operational requirements. A growing telehealth company should evaluate the entire pharmacy workflow rather than choosing based on the 503A or 503B label alone.
Can 503A and 503B pharmacies compound GLP-1 medications?
Potentially, depending on the specific medication, substance, formulation, shortage status, prescription requirements, and applicable federal and state rules. Being a 503A or 503B facility does not automatically authorize a pharmacy to compound every GLP-1 product.
What compliance requirements apply to 503A and 503B pharmacies?
They have different requirements. 503A compounding is subject to conditions including patient-specific prescription requirements and restrictions on essentially copying commercially available drugs. 503B outsourcing facilities must register with FDA, comply with CGMP requirements, meet applicable compounding conditions, report adverse events, and provide certain product information to FDA.
How should a telehealth brand choose between a 503A and 503B pharmacy?
Start with your actual operating model. Look at where you prescribe, what you prescribe, expected prescription volume, refill frequency, pharmacy coverage, capacity, prescription routing, fulfillment visibility, and compliance requirements. Then verify the pharmacy’s licensing, regulatory status, product capabilities, and operational processes before making it part of your infrastructure.